The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment
- 1 October 2012
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 31 (10), 2276-2285
- https://doi.org/10.1377/hlthaff.2011.1120
Abstract
Statins are considered a clinically important breakthrough for the treatment of cardiovascular disease. However, their social value at the US population level has not previously been studied. From an economic perspective, social value measures the quantity of resources—in monetary terms—that society would be willing to give up in order to retain the survival gains resulting from statin therapy. Using combined population and clinical data, this article calculates statins’ social value to consumers, or the value of survival benefits above actual payments for the drug, and to producers, or drug revenues, for the period 1987–2008. National survey data suggest that statin therapy reduced low-density lipoprotein levels by 18.8 percent, which translated into roughly 40,000 fewer deaths, 60,000 fewer hospitalizations for heart attacks, and 22,000 fewer hospitalizations for strokes in 2008. For people starting statin therapy in 1987–2008, consumers captured $947.4 billion (76 percent) of the total social value of the survival gains. Even greater consumer benefits could be achieved in the future if statins were prescribed in full compliance with cholesterol guidelines and patients adhered to prescribed regimens. In addition, statin costs are declining because of patent expirations. Policy makers should consider interventions at the patient and provider levels to encourage both therapy for untreated patients with high cholesterol and greater adherence after therapy is initiated.Keywords
This publication has 25 references indexed in Scilit:
- Statins: Is It Really Time to Reassess Benefits and Risks?New England Journal of Medicine, 2012
- Cost Estimation of Cardiovascular Disease Events in the USPharmacoEconomics, 2011
- Heart Disease and Stroke Statistics—2011 UpdateCell Metabolism, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Health Spending Growth At A Historic Low In 2008Health Affairs, 2010
- Impact of a Prescription Copayment Increase on Lipid-Lowering Medication Adherence in VeteransCell Metabolism, 2009
- A test of financial incentives to improve warfarin adherenceBMC Health Services Research, 2008
- Effect of financial incentives on inequalities in the delivery of primary clinical care in England: analysis of clinical activity indicators for the quality and outcomes frameworkThe Lancet, 2008
- The Value Of Antihypertensive Drugs: A Perspective On Medical InnovationHealth Affairs, 2007
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000